Pulse methylprednisolone therapy in children with membranoproliferative glomerulonephritis. 1995

S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
Department of Pediatric Nephrology, University of Istanbul, Turkey.

The effects of pulse methylprednisolone (PM) therapy were studied in 15 patients (aged 3-14 years) with biopsy proven membranoproliferative glomerulonephritis (MPGN). Patients were treated with intravenous PM 30 mg/kg (max 1 g) given over 30 min every other day for a mean of 9.8 days (3-15 days). Oral prednisolone therapy was continued at a dose of 1 mg/kg/24 h for 1 month and subsequently tapered off the following month. Eight patients had hematuria and six had medically controlled hypertension. Serum C3 levels were low in 11 patients and all of the patients had proteinuria. Following PM therapy proteinuria was significantly reduced from 2602.9 +/- 1852.5 mg/24 h to 1871.2 +/- 2090.8 mg/24 h (P < 0.05) and at final evaluation, proteinuria was 774.33 +/- 1225.67 mg/24 h which was significantly lower than pre- and post-PM therapy values (P < 0.05). Serum creatinine levels were high in five patients before PM therapy and remained high in one of the patients who progressed to end-stage renal failure. After PM therapy, high serum creatinine levels normalized in three patients and was reduced, but still above normal, in one. One patient, with initially normal serum creatinine, had elevated levels afterwards. Nine of the patients were considered responsive and six non-responsive according to our tentatively defined criteria. Mean follow-up period was 27.4 +/- 24.1 months (6-84 months). Three patients were lost for follow-up, and 12 were re-evaluated.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D015432 Glomerulonephritis, Membranoproliferative Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN. C3G Complement 3 Glomerulopathy,Complement 3 Glomerulopathies,Complement 3 Glomerulopathy,Glomerulonephritis, Mesangiocapillary,MPGN Membranoproliferative Glomerulonephritis,Membranoproliferative Glomerulonephritis,Mesangiocapillary Glomerulonephritis,DDD MPGNII,Dense Deposit Disease,Glomerulonephritis, Hypocomplementemic,MPGNII,Membranoproliferative Glomerulonephritis Type II,Membranoproliferative Glomerulonephritis, Type I,Membranoproliferative Glomerulonephritis, Type II,Membranoproliferative Glomerulonephritis, Type III,Mesangiocapillary Glomerulonephritis, Type I,Mesangiocapillary Glomerulonephritis, Type II,Subendothelial Membranoproliferative Glomerulonephritis,Type II MPGN,DDD MPGNIIs,Glomerulonephritides, MPGN Membranoproliferative,Glomerulonephritides, Membranoproliferative,Glomerulonephritis, MPGN Membranoproliferative,Glomerulopathies, Complement 3,Glomerulopathy, Complement 3,Hypocomplementemic Glomerulonephritides,Hypocomplementemic Glomerulonephritis,MPGN Membranoproliferative Glomerulonephritides,MPGN, Type II,MPGNII, DDD,MPGNIIs,Membranoproliferative Glomerulonephritides,Membranoproliferative Glomerulonephritides, MPGN,Membranoproliferative Glomerulonephritis, MPGN,Membranoproliferative Glomerulonephritis, Subendothelial,Mesangiocapillary Glomerulonephritides,Type II MPGNs

Related Publications

S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
June 1978, Nihon Jinzo Gakkai shi,
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
June 1995, Pediatric nephrology (Berlin, Germany),
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
January 1989, American journal of nephrology,
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
April 1991, The Netherlands journal of medicine,
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
April 1980, Annals of internal medicine,
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
November 1985, The Journal of pediatrics,
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
February 1976, The Journal of pediatrics,
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
July 1985, Ceskoslovenska pediatrie,
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
January 2001, Lupus,
S Emre, and A Sirin, and H Alpay, and F Tanman, and V Uysal, and A Nayir, and I Bilge
January 2010, Fetal and pediatric pathology,
Copied contents to your clipboard!